Evolution and predictive factors of thyroid disorder due to interferon alpha in the treatment of hepatitis C

Table 3 Features associated with dysthyroidism

	With dysthyroidism	Without dysthyroidism	P
Age1 (yr)	46.20 ± 10.08	48.49 ± 11.96	0.40
Female (%)	56.9	40.9	0.05
Contamination mode (%)
Transfusion	33.3	26.6
Drug-addict	20.0	27.7
Blood exposure accident	13.3	7.0
Others	33.3	38.7
Genotype (%, 1/2/3/4/5/6/ND)	57/13/13/0/0/0/17	33/11/20/9/1/0/26	0.20
Stage of fibrosis < F2 (%)	30.0	10.3	0.009
Type of treatment (%)
IFNα	3.3	3.3
Peg-interferon	6.7	9.3
IFNα + ribavirin	16.7	28.5
Peg-interferon + ribavirin	73.3	58.9
Duration of treatment1 (mo )	7.73 ± 3.64	8.09 ± 3.93	0.30
Positive antibodies before treatment (%)
TPOAb	26.9	2.5	< 0.0003
TgAb	18.5	1.5	0.0003
TSHRAb	0.0	1.3	0.42

ND: Not determined.

¹mean ± SD.